Indegene Limited delivered a landmark revenue milestone in Q4 FY26 — crossing Rs 1,000 crore in quarterly revenue for the first time — but the headline number was overshadowed by a 32% collapse in net profit and a significant margin contraction that has raised questions about the cost structure of the pharma technology company’s rapid growth.
Revenue for Q4 FY26 grew 32.8% year-on-year to Rs 1,003.4 crore from Rs 755.6 crore, a strong topline showing that reflects the continued scaling of Indegene’s digital and commercial solutions business for global pharmaceutical clients. EBITDA rose a more modest 10.9% to Rs 163.6 crore from Rs 147.5 crore — a meaningful divergence from the revenue growth rate that tells the core story of the quarter.
EBITDA margin contracted sharply to 16.3% from 19.5% a year ago — a 320 basis point compression that signals costs are growing materially faster than revenue. Net profit fell 32.2% to Rs 79.7 crore from Rs 117.6 crore in Q4 FY25, a steep decline that reflects both the operating margin pressure and likely elevated depreciation, amortisation and finance costs below the EBITDA line — consistent with a company that has been investing aggressively in capabilities, talent and technology infrastructure to support its global pharma client base.
Why profit fell despite strong revenue growth
The disconnect between 33% revenue growth and a 32% profit decline is stark and warrants explanation. Three factors are likely at play. First, the 320 basis point EBITDA margin compression points to a significant increase in operating costs — employee expenses in particular tend to scale faster than revenue in a services business when hiring accelerates ahead of revenue conversion. Second, Indegene has been integrating acquisitions and expanding its global delivery footprint, both of which carry transition costs that weigh on near-term profitability. Third, any increase in depreciation and amortisation from capitalised investments or acquired intangibles would further compress reported PAT even if EBITDA held firm.
The stock, trading at Rs 504.05 — up 1.74% on the day — is holding its ground despite the weak profit print, suggesting the market is treating the margin compression as cyclical rather than structural, and focusing instead on the revenue trajectory and the significance of the Rs 1,000 crore quarterly milestone. At a PE of 27.60 and a market cap of approximately Rs 12,117 crore, the valuation is pricing in a recovery in margins as investments begin to yield operating leverage.
Whether that recovery materialises in FY27 will be the central question for Indegene investors going forward.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a qualified financial advisor before making investment decisions.